JP2009537568A5 - - Google Patents

Download PDF

Info

Publication number
JP2009537568A5
JP2009537568A5 JP2009511250A JP2009511250A JP2009537568A5 JP 2009537568 A5 JP2009537568 A5 JP 2009537568A5 JP 2009511250 A JP2009511250 A JP 2009511250A JP 2009511250 A JP2009511250 A JP 2009511250A JP 2009537568 A5 JP2009537568 A5 JP 2009537568A5
Authority
JP
Japan
Prior art keywords
composition
phosphodiesterase
pde4
cognitive
training
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009511250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537568A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/069279 external-priority patent/WO2007137181A2/en
Publication of JP2009537568A publication Critical patent/JP2009537568A/ja
Publication of JP2009537568A5 publication Critical patent/JP2009537568A5/ja
Pending legal-status Critical Current

Links

JP2009511250A 2006-05-19 2007-05-18 認知および運動のリハビリテーションのためのホスホジエステラーゼ４インヒビター Pending JP2009537568A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80194906P 2006-05-19 2006-05-19
PCT/US2007/069279 WO2007137181A2 (en) 2006-05-19 2007-05-18 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014220896A Division JP2015042667A (ja) 2006-05-19 2014-10-30 認知および運動のリハビリテーションのためのホスホジエステラーゼ４インヒビター

Publications (2)

Publication Number Publication Date
JP2009537568A JP2009537568A (ja) 2009-10-29
JP2009537568A5 true JP2009537568A5 (cg-RX-API-DMAC10.html) 2010-07-01

Family

ID=38617977

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009511250A Pending JP2009537568A (ja) 2006-05-19 2007-05-18 認知および運動のリハビリテーションのためのホスホジエステラーゼ４インヒビター
JP2014220896A Pending JP2015042667A (ja) 2006-05-19 2014-10-30 認知および運動のリハビリテーションのためのホスホジエステラーゼ４インヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014220896A Pending JP2015042667A (ja) 2006-05-19 2014-10-30 認知および運動のリハビリテーションのためのホスホジエステラーゼ４インヒビター

Country Status (11)

Country Link
EP (2) EP2377533A3 (cg-RX-API-DMAC10.html)
JP (2) JP2009537568A (cg-RX-API-DMAC10.html)
CN (1) CN101500559B (cg-RX-API-DMAC10.html)
AU (1) AU2007253734B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0711816A2 (cg-RX-API-DMAC10.html)
CA (1) CA2653042C (cg-RX-API-DMAC10.html)
ES (1) ES2412481T3 (cg-RX-API-DMAC10.html)
IL (1) IL195295A (cg-RX-API-DMAC10.html)
MX (1) MX2008014713A (cg-RX-API-DMAC10.html)
SG (2) SG10201407258RA (cg-RX-API-DMAC10.html)
WO (1) WO2007137181A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US7947731B2 (en) 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
BRPI0916228A2 (pt) * 2008-07-18 2015-11-03 Dart Neuroscience Llc métodos e sistemas para avaliação de agentes de memória
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
US9727691B2 (en) 2011-09-30 2017-08-08 Tokyo Metropolitan Institute Of Medical Science Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic AMP responsive element binding protein gene
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
CA3103781C (en) * 2019-12-23 2023-02-14 Peter Anthony Hall Method and system for assessing cognitive function of an individual

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
FI944549L (fi) 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
AU678158B2 (en) 1992-04-10 1997-05-22 Fox Chase Cancer Center Transcription control element for increasing gene expression in myoblasts
JP2001508020A (ja) * 1994-06-02 2001-06-19 シエーリング アクチエンゲゼルシヤフト 多発性硬化症治療用のｐｄｅ ｉｖ阻害剤
EP0781335A1 (en) 1994-10-07 1997-07-02 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
US5929223A (en) 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
WO2000014083A1 (en) 1998-09-09 2000-03-16 Inflazyme Pharmaceuticals Ltd. SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
WO2000050402A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
CA2402384A1 (en) 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
US7947731B2 (en) * 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
JP2004532809A (ja) * 2000-11-02 2004-10-28 リサーチ ファウンデーション オブ シティ ユニバーシティ オブ ニューヨーク ホスホジエステラーゼ４型を阻害することによって、神経系の再生および修復を刺激するための方法
WO2003032981A1 (en) * 2001-10-16 2003-04-24 Memory Pharmaceuticals Corporation 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
AU2003210869A1 (en) * 2002-02-07 2003-09-02 University Of Miami Schwann cell and phosphodiesterase inhibitors based therapy
WO2004082624A2 (en) * 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. Modafinil-based neurorehabilitation of impaired neurological function associated with injury
US20090298864A1 (en) * 2005-04-11 2009-12-03 The Trustees Of Columbia University In The City Of New York Methods for Treating Mild Cognitive Impairment

Similar Documents

Publication Publication Date Title
Salamone et al. Mesolimbic dopamine and the regulation of motivated behavior
Celada et al. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research
Hasan et al. Impaired long-term depression in schizophrenia: a cathodal tDCS pilot study
Leiser et al. A cog in cognition: how the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits
Furlong et al. The effect of air puff stress on c‐Fos expression in rat hypothalamus and brainstem: Central circuitry mediating sympathoexcitation and baroreflex resetting
Svensson Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs
Liu et al. The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia
McCarthy et al. Glutamate-based depression GBD
Bhagya et al. Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression
Ide et al. Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine
EP2633868A1 (en) Combination of alpha 7 nicotinic agonists and antipsychotics
Rummel et al. Testing different paradigms to optimize antidepressant deep brain stimulation in different rat models of depression
Smucny et al. Could vagus nerve stimulation target hippocampal hyperactivity to improve cognition in schizophrenia?
TN2009000277A1 (en) 3-substituted -[1,2,3]- benzotriazinone compound for enhancing glutamatergic synaptic reponses
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
Nin et al. The effect of intra-nucleus accumbens administration of allopregnanolone on δ and γ2 GABAA receptor subunit mRNA expression in the hippocampus and on depressive-like and grooming behaviors in rats
RS61442B1 (sr) Farmaceutske kombinacije i upotrebe usmerene na poremećaje lizozomalnog skladištenja
Floel et al. Translational studies in neurorehabilitation: from bench to bedside
JP2006524243A5 (cg-RX-API-DMAC10.html)
Cui et al. Sleep patterns deteriorate over time in chronic corticosterone-treated rats
Moreau et al. Chronic intermittent hypoxia induces changes in expression of synaptic proteins in the nucleus of the solitary tract
Hasan et al. Investigations of motor-cortex cortical plasticity following facilitatory and inhibitory transcranial theta-burst stimulation in schizophrenia: a proof-of-concept study
Aliane et al. Raclopride or high‐frequency stimulation of the subthalamic nucleus stops cocaine‐induced motor stereotypy and restores related alterations in prefrontal basal ganglia circuits
Wolsh et al. Extensive complex neocortical movement topography devolves to simple output following experimental stroke in mice
Meng et al. Using electroacupuncture at acupoints to predict the efficacy of hippocampal high-frequency electrical stimulation in pharmacoresistant temporal lobe epilepsy patients